Zileuton suppresses cholangiocarcinoma cell proliferation and migration through inhibition of the Akt signaling pathway
BACKGROUND: Inflammatory lipid mediators play an important role in several cancer types. Leukotrienes (LTs), pro-inflammatory lipid mediators, are involved in chronic inflammation and cancer progression. They are derived from arachidonic acid by 5-lipoxygenase (5-LOX) activity. On the other hand, 15-lipoxygenase (15-LOX-1) converts LTs into lipoxins (LXs), pro-resolving lipid mediators. LXs are involved in the attenuation of inflammation and cancer development.
PURPOSE: We aimed to investigate the lipid mediator pathways, especially the LTs and LXs pathways, by studying 5-LOX and 15-LOX-1 expression in human cholangiocarcinoma (CCA) tissue. We also investigated the efficiency of zileuton (5-LOX inhibitor) treatment and BML-111 (LXA4 analog) addition on CCA cell lines properties.
PATIENTS AND METHODS: The expression of 5-LOX and 15-LOX-1 in fifty human cholangiocarcinoma (CCA) tissue was analyzed using immunohistochemical staining. In addition, the effect of zileuton and BML-111 on CCA cell growth and migration was demonstrated using a cell viability assay and wound-healing assay, respectively. Furthermore, the molecular mechanism by which zileuton inhibits CCA cell migration was revealed using immunofluorescent staining and western blot analysis, respectively.
RESULTS: We demonstrate that the upregulation of 5-LOX is significantly correlated with CCA recurrent status. A positive 15-LOX-1 signal was significantly associated with a longer survival time in CCA patients. We found that co-expression of 5-LOX and 15-LOX-1 resulted in a relatively good prognosis in CCA patients. In addition, zileuton could inhibit CCA cell migration as well as BML-111. Interestingly, zileuton treatment not only downregulated 5-LOX, but also upregulated 15-LOX-1, together with reversing the epithelial-mesenchymal transition to mesenchymal-epithelial transition phenotype as observed in EMT marker western blot.
CONCLUSION: These findings suggest that 5-LOX and 15-LOX-1 play a key role in CCA and may serve as targets for CCA therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
OncoTargets and therapy - 11(2018) vom: 01., Seite 7019-7029 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khophai, Sasikamon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
15-LOX-1 |
|---|
| Anmerkungen: |
Date Revised 30.03.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/OTT.S178942 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290431042 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290431042 | ||
| 003 | DE-627 | ||
| 005 | 20231225064723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/OTT.S178942 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0968.xml |
| 035 | |a (DE-627)NLM290431042 | ||
| 035 | |a (NLM)30410359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khophai, Sasikamon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Zileuton suppresses cholangiocarcinoma cell proliferation and migration through inhibition of the Akt signaling pathway |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Inflammatory lipid mediators play an important role in several cancer types. Leukotrienes (LTs), pro-inflammatory lipid mediators, are involved in chronic inflammation and cancer progression. They are derived from arachidonic acid by 5-lipoxygenase (5-LOX) activity. On the other hand, 15-lipoxygenase (15-LOX-1) converts LTs into lipoxins (LXs), pro-resolving lipid mediators. LXs are involved in the attenuation of inflammation and cancer development | ||
| 520 | |a PURPOSE: We aimed to investigate the lipid mediator pathways, especially the LTs and LXs pathways, by studying 5-LOX and 15-LOX-1 expression in human cholangiocarcinoma (CCA) tissue. We also investigated the efficiency of zileuton (5-LOX inhibitor) treatment and BML-111 (LXA4 analog) addition on CCA cell lines properties | ||
| 520 | |a PATIENTS AND METHODS: The expression of 5-LOX and 15-LOX-1 in fifty human cholangiocarcinoma (CCA) tissue was analyzed using immunohistochemical staining. In addition, the effect of zileuton and BML-111 on CCA cell growth and migration was demonstrated using a cell viability assay and wound-healing assay, respectively. Furthermore, the molecular mechanism by which zileuton inhibits CCA cell migration was revealed using immunofluorescent staining and western blot analysis, respectively | ||
| 520 | |a RESULTS: We demonstrate that the upregulation of 5-LOX is significantly correlated with CCA recurrent status. A positive 15-LOX-1 signal was significantly associated with a longer survival time in CCA patients. We found that co-expression of 5-LOX and 15-LOX-1 resulted in a relatively good prognosis in CCA patients. In addition, zileuton could inhibit CCA cell migration as well as BML-111. Interestingly, zileuton treatment not only downregulated 5-LOX, but also upregulated 15-LOX-1, together with reversing the epithelial-mesenchymal transition to mesenchymal-epithelial transition phenotype as observed in EMT marker western blot | ||
| 520 | |a CONCLUSION: These findings suggest that 5-LOX and 15-LOX-1 play a key role in CCA and may serve as targets for CCA therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 15-LOX-1 | |
| 650 | 4 | |a 5-LOX | |
| 650 | 4 | |a Akt pathway | |
| 650 | 4 | |a EMT | |
| 650 | 4 | |a cholangiocarcinoma | |
| 650 | 4 | |a zileuton | |
| 700 | 1 | |a Thanee, Malinee |e verfasserin |4 aut | |
| 700 | 1 | |a Techasen, Anchalee |e verfasserin |4 aut | |
| 700 | 1 | |a Namwat, Nisana |e verfasserin |4 aut | |
| 700 | 1 | |a Klanrit, Poramate |e verfasserin |4 aut | |
| 700 | 1 | |a Titapun, Attapol |e verfasserin |4 aut | |
| 700 | 1 | |a Jarearnrat, Apiwat |e verfasserin |4 aut | |
| 700 | 1 | |a Sa-Ngiamwibool, Prakasit |e verfasserin |4 aut | |
| 700 | 1 | |a Loilome, Watcharin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t OncoTargets and therapy |d 2008 |g 11(2018) vom: 01., Seite 7019-7029 |w (DE-627)NLM199447950 |x 1178-6930 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2018 |g day:01 |g pages:7019-7029 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/OTT.S178942 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2018 |b 01 |h 7019-7029 | ||